BioAge Labs Management
Management criteria checks 1/4
BioAge Labs' CEO is Kristen Fortney, appointed in Apr 2015, has a tenure of 9.75 years. total yearly compensation is $1.38M, comprised of 35.7% salary and 64.3% bonuses, including company stock and options. directly owns 3.38% of the company’s shares, worth €6.30M. The average tenure of the management team and the board of directors is 4 years and 0.8 years respectively.
Key information
Kristen Fortney
Chief executive officer
US$1.4m
Total compensation
| CEO salary percentage | 35.7% |
| CEO tenure | 9.8yrs |
| CEO ownership | 3.4% |
| Management average tenure | 4yrs |
| Board average tenure | less than a year |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$71m |
| Jun 30 2024 | n/a | n/a | -US$62m |
| Mar 31 2024 | n/a | n/a | -US$66m |
| Dec 31 2023 | US$1m | US$493k | -US$64m |
Compensation vs Market: Kristen's total compensation ($USD1.38M) is above average for companies of similar size in the German market ($USD837.57K).
Compensation vs Earnings: Insufficient data to compare Kristen's compensation with company performance.
CEO
Kristen Fortney (41 yo)
9.8yrs
Tenure
US$1,382,720
Compensation
Dr. Kristen Fortney, PhD, serves as Member of Advisory Board at Known Medicine Inc. since April 2022. She co-founded BioAge Labs, Inc. in 2015 and serves as Chief Executive Officer, President, Treasurer, S...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$1.38m | 3.38% € 6.3m | |
| Co-Founder | 4.7yrs | US$872.80k | 0.19% € 350.0k | |
| Chief Medical Officer & Executive VP of Research | 4.7yrs | US$840.83k | no data | |
| Chief Financial Officer | 3.2yrs | no data | 0.063% € 116.7k | |
| Vice President of Finance & Accounting | 3.8yrs | no data | no data | |
| Senior Vice President of Research | no data | no data | no data | |
| Senior Vice President of People | 3yrs | no data | no data | |
| Chief Business Officer & Therapeutic Area Head of Brain Aging | 5.8yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | 5yrs | no data | no data | |
| Senior Vice President of Translational Aging Biology | 3.8yrs | no data | no data | |
| Chief Strategy Officer | 4yrs | no data | no data | |
| Chief Development Officer | 3.2yrs | no data | no data |
4.0yrs
Average Tenure
49.5yo
Average Age
Experienced Management: Y7G's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$1.38m | 3.38% € 6.3m | |
| Co-Founder | 7.6yrs | US$872.80k | 0.19% € 350.0k | |
| Independent Director | less than a year | no data | no data | |
| Independent Chairman of the Board | less than a year | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 7.6yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Independent Director | 3.4yrs | US$40.00k | 0% € 0 | |
| Member of Scientific Advisory Board | less than a year | no data | no data |
0.8yrs
Average Tenure
59yo
Average Age
Experienced Board: Y7G's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/08 12:27 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioAge Labs, Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samantha Lynn Semenkow | Citigroup Inc |
| Salveen Richter | Goldman Sachs |
| Roger Song | Jefferies LLC |